Literature DB >> 19006547

Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.

Guido Bocci, Antonello Di Paolo, Cecilia Barbara, Gianluca Masi, Lorenzo Fornaro, Fotios Loupakis, Giacomo Allegrini, Alfredo Falcone, Mario Del Tacca, Romano Danesi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19006547      PMCID： PMC2668095          DOI： 10.1111/j.1365-2125.2008.03307.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.

Authors:  Hany H Ezzeldin; Adam M Lee; Lori K Mattison; Robert B Diasio
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

2.  A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.

Authors:  Guido Bocci; Cecilia Barbara; Francesca Vannozzi; Antonello Di Paolo; Alessandro Melosi; Gemma Barsanti; Giacomo Allegrini; Alfredo Falcone; Mario Del Tacca; Romano Danesi
Journal:  Clin Pharmacol Ther       Date:  2006-10       Impact factor: 6.875

Review 3.  Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.

Authors:  Cédric Mercier; Joseph Ciccolini
Journal:  Clin Colorectal Cancer       Date:  2006-11       Impact factor: 4.481

4.  Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography.

Authors:  S P Ackland; M B Garg; R H Dunstan
Journal:  Anal Biochem       Date:  1997-03-01       Impact factor: 3.365

5.  Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.

Authors:  G Bocci; R Danesi; G Allegrini; F Innocenti; A Di Paolo; A Falcone; P F Conte; M Del Tacca
Journal:  Eur J Clin Pharmacol       Date:  2002-12       Impact factor: 2.953

6.  Population study of dihydropyrimidine dehydrogenase in cancer patients.

Authors:  M C Etienne; J L Lagrange; O Dassonville; R Fleming; A Thyss; N Renée; M Schneider; F Demard; G Milano
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.

Authors:  Lori K Mattison; Hany Ezzeldin; Mark Carpenter; Anil Modak; Martin R Johnson; Robert B Diasio
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

8.  A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.

Authors:  J Ciccolini; C Mercier; M-F Blachon; R Favre; A Durand; B Lacarelle
Journal:  J Clin Pharm Ther       Date:  2004-08       Impact factor: 2.512

9.  Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.

Authors:  Joachim Fischer; Matthias Schwab; Michel Eichelbaum; Ulrich M Zanger
Journal:  Genet Test       Date:  2003

10.  Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity.

Authors:  Madhu B Garg; Jade C Sevester; Jennette A Sakoff; Stephen P Ackland
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-07-15       Impact factor: 3.205
View more
  3 in total

1.  Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.

Authors:  Manon Launay; Laetitia Dahan; Manon Duval; Anne Rodallec; Gérard Milano; Muriel Duluc; Bruno Lacarelle; Joseph Ciccolini; Jean-Francois Seitz
Journal:  Br J Clin Pharmacol       Date:  2015-11-28       Impact factor: 4.335

2.  In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity.

Authors:  Raphaelle Fanciullino; Séverine Mollard; Sarah Giacometti; Yael Berda-Haddad; Mohamed Chefrour; Claude Aubert; Athanassios Iliadis; Joseph Ciccolini
Journal:  Pharm Res       Date:  2013-02-06       Impact factor: 4.200

3.  A practical approach for assessing chemosensitivity in colorectal cancer cell lines by comparative analysis of cell viability and thymidylate synthase mRNA expression.

Authors:  Hyun Yong Hwang
Journal:  J Korean Surg Soc       Date:  2011-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.